Virtual Library
Start Your Search
Y. Yue
Author of
-
+
P1.05 - Poster Session with Presenters Present (ID 457)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.05-045 - Adjuvant Chemotherapy for Patients with Stage IB Non Small Cell Lung Cancer (ID 4565)
14:30 - 15:45 | Author(s): Y. Yue
- Abstract
Background:
The prognosis of stage Ib non-small cell lung cancer (NSCLC) remains poor, there’re much controversy over the necessity of adjuvant chemotherapy to them. The aim of this study is to investigate the clinical characters influencing prognosis of the stage Ib non-small cell lung cancer (NSCLC) and to explore the indication of postoperative chemotherapy.
Methods:
In total, 569 stage IB patients with NSCLC who underwent surgical resection with or without adjuvant therapy were included in this study. Cox proportional-hazards ratios were used to identify independent prognostic factors for survival. Kaplan-Meier survival curves were calculated to estimate survival rates.
Results:
Adjuvant chemotherapy, tumor size and performance status were independent prognostic factors in the univariate and multivariate analyses. Patients with tumor greater than 4 cm and patients with good performance status benefitted from adjuvant chemotherapy. On the contrary, to the patients with tumor less or equal to 4 cm or patients without good performance status, giving adjuvant chemotherapy is not better than giving surgery alone. Figure 1 Figure 2
Conclusion:
Adjuvant chemotherapy, tumor size and performance status were closely correlated with survival in the stage Ib NSCLC, patients with tumor greater than 4 cm and patients with good performance status benefitted from adjuvant chemotherapy.
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-056 - FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non-Small Cell Lung Cancer, and Associated with Lymph Node Metastasis (ID 4308)
14:30 - 15:45 | Author(s): Y. Yue
- Abstract
Background:
Targeting FGFRs is one of the most promising therapeutic strategies in squamous non-small cell lung cancer (SQCC). However, different FGFR genomic aberrations can be associated with distinct biological characteristics that result in different clinical outcomes or therapeutic consequences. Currently, the full spectrum of FGFR gene aberrations and their clinical significance in SQCC have not been comprehensively studied.
Methods:
Next-generation sequencing was used to investigate FGFR gene mutations in 143 patients with SQCC who had not been treated with chemotherapy or radiotherapy prior to surgery.
Results:
FGFR gene mutations were identified in 24 cases, resulting in an overall frequency of 16.9%. Among the mutations, 7% (10/143) were somatic mutations, and 9.8% (14/143) germline mutations. FGFR mutations were significantly associated with an increased risk of lymph node metastasis (adjusted OR = 4.75, 95% CI = 1.78-12.7, P = 0.002). SQCC patients with a FGFR somatic mutation had shorter OS (overall survival, log rank P = 0.008) and DFS (disease-free survival，log rank P = 0.006) compared with those without an FGFR mutation. The multivariate analysis confirmed that a somatic mutation was an independent poor prognostic factor for OS (HR: 2.76, 95% CI: 1.05-7.27, P = 0.04) and was associated with reduced DFS (HR: 2.22, 95% CI: 0.97-5.07, P = 0.06). Figure 1
Conclusion:
FGFR mutation may increase the risk of lymph node metastasis in patients with SQCC. FGFR somatic mutation could be a useful biomarker for predicting poor clinical outcome in SQCC.
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-051 - CMTM1_v17 Promotes Chemotherapy Resistance and is Associated with Poor Prognosis in Non-Small Cell Lung Cancer (ID 4371)
14:30 - 15:45 | Author(s): Y. Yue
- Abstract
Background:
Despite a consistent rate of initial responses, chemotherapy treatment often results in the development of chemoresistance, leading to therapeutic failure in non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with cisplatin-based neo-adjuvant chemotherapy (NAC) response
Methods:
31 pairs of tumor tissues before and after NAC and 78 resected tumor tissues after NAC were utilized for immunohistochemistry (IHC) staining of CMTM1_v17 protein. Flow cytometry was used to detect the change of CMTM1_v17 expression in NSCLC patient-derived xenografts (PDX models) with cisplatin treatment.
Results:
CMTM1_v17 expression was found to be significantly related to treatment effect and outcome in the tumor tissues after NAC but not in the tissues before NAC from the 31 cases of NSCLC. We identified that high CMTM1_v17 expression was associated with low objective remission rate (ORR) (p=0.008) and poor prognosis (the median OS: 35.1 months vs 65.6 months，p=0.0045；the median DFS: 17.27 months vs 35.54 months，p=0.0207) in the 31 patients. Next, we detected CMTM1_v17 expression to confirm correlation between this protein status and clinical characteristics in 78 NSCLC patients with NAC. The up-regulation of CMTM1_v17 had a higher SD rate (p=0.007) and worse outcome ( the median OS: 41.0 months vs 80.6 months, p=0.0028；the median DFS: 33.4 months vs 64.8 months，p=0.0032). COX multivariate analysis indicated that CMTM1_v17 is an independent prognostic risk factor on patients who received NAC (OS：HR=3.642，p=0.002；DFS：HR=2.867，p=0.003). Then, we tested CMTM1_v17 expression in the lung cancer PDX mice with different treatment, showing that this protein was up-regulated in the tumor tissues received cisplatin treatment, compared to the tumor tissues with saline stimulation of control group.
Conclusion:
CMTM_v17 expression was significantly associated with chemoresistance and poor prognosis of the early stage NSCLC patients who received NAC. Cisplatin could induce the expression of CMTM1_v17 in lung cancer cells from PDX model.
